Latest News

In March 2026, Revolve Group, Inc. launched Revolve Los Angeles, its first namesake fashion house, debuting a XXS–XL collection priced around US$200–US$3,500 and sold exclusively on Revolve and FWRD. The move expands Revolve’s in-house brand portfolio into higher-end, couture-influenced ready-to-wear, potentially deepening customer engagement around luxury, Los Angeles-inspired fashion. Next, we’ll examine how Revolve Los Angeles, as a higher-end in-house label, could influence Revolve...

What Barclays stock’s recent performance tells you With no single headline event driving the story, Barclays (LSE:BARC) has still drawn attention after a one-month return of about a 15% decline and a past three-month decline of roughly 14%. See our latest analysis for Barclays. That recent share price weakness, including a 1-month share price return of about a 15% decline and a year to date share price return of roughly a 19% decline from £3.8625, contrasts with a much stronger picture on...

Earlier this month, Hess Midstream LP announced that its Board authorized a share repurchase program and entered into an agreement with JPMorgan Chase Bank to buy back up to US$42 million of Class A shares, funded through its existing revolving credit facility, with repurchased shares to be cancelled and final settlement expected by March 2026. This accelerated share repurchase arrangement not only reduces the public float but also underscores management’s willingness to use balance sheet...

Shanghai Henlius Biotech (SEHK:2696) has drawn fresh attention after China’s National Medical Products Administration approved phase 1 trials for two solid tumour candidates, HLX316 and HLX3901, both backed by positive preclinical safety and efficacy data. See our latest analysis for Shanghai Henlius Biotech. The recent NMPA green light for HLX316 and HLX3901 comes as Shanghai Henlius Biotech’s share price sits at HK$67.95, with a 90 day share price return of 13.53% and a very large 3 year...

In recent days, Moelis & Company reported strong Q4 earnings and highlighted its strongest coverage platform to date, with management emphasizing momentum and long-term value creation. At the same time, several major banks reiterated neutral views on Moelis, revealing a tension between upbeat internal commentary and cautious external assessments. Next, we'll examine how upbeat earnings alongside cautious analyst sentiment may influence Moelis' existing investment narrative around growth...

In early March 2026, U.S. Bancorp expanded its funding options with a series of new senior unsecured fixed-rate notes maturing between 2031 and 2046, while also declaring regular quarterly and semi-annual dividends on its common and multiple preferred share classes payable on April 15, 2026. The creation of a President of Emerging Affluent Wealth Management role, alongside fresh bond issuance and an updated universal shelf registration, points to a coordinated push to deepen relationships...

Genscript Biotech has reported its full-year 2025 results, with sales rising to US$959.53 million while the company moved from a prior-year net income of US$2.96 billion to a net loss of US$532.83 million, alongside higher basic and diluted losses per share. A key driver of this sharp swing in reported profitability is the absence of the previous year’s very large one-time unrealised gain from deconsolidation, which means the latest figures chiefly reflect the underlying operating profile...

In recent days, Department of Justice documents revealed that Ubiquiti’s networking equipment was used for communications and surveillance on Jeffrey Epstein’s private island, drawing public and regulatory attention to the company’s role. This association creates a new layer of reputational and legal risk for Ubiquiti, complicating an investment story previously focused on balance sheet strength and earnings momentum. We’ll now examine how this emerging reputational and regulatory risk...

In recent days, Opendoor Technologies reported Q4 revenue that exceeded analyst expectations while guiding to a roughly 10% year-on-year revenue decline for Q1 and an adjusted EBITDA loss. Management highlighted progress in unit economics, growth of its low-capital Cash Plus offering, cost reductions, and a new 4.99% beta mortgage program that together point to an evolving, more flexible business model. Next, we’ll examine how Opendoor’s stronger-than-expected Q4 revenue and improved unit...

On March 10, 2026, Amalgamated Financial Corp reported fourth-quarter 2025 earnings with earnings per share of $0.91, matching analyst expectations, while quarterly revenue of $87.91 million modestly exceeded forecasts. On the same day, Executive Vice President and Chief Legal Officer Mandy Tenner sold 776 shares under a Rule 10b5-1 plan, adding to a year of insider selling that raises questions about how leadership is managing personal holdings alongside solid operating results. Next,...

Sinch (OM:SINCH) has put its Enterprise Voice platform in focus with the launch of Voice Relay, a tool that links text-based AI agents to live calls and aims to simplify complex voice automation. See our latest analysis for Sinch. The new Voice Relay launch comes as Sinch’s share price, at SEK23.11, shows mixed momentum, with a 1-week share price return of 2.89% but a 3-month share price return decline of 24.18%. The 5-year total shareholder return decline of 84.74% underlines how long term...

In recent weeks, AppLovin has highlighted its expansion beyond mobile gaming into e-commerce advertising, including plans to roll out a self-service ad platform and AI-powered tools for smaller developers and merchants. An interesting angle is how AppLovin is pairing this push with heavy share repurchases, effectively using its high-margin cash generation to both broaden its advertiser base and shrink its share count. Next, we’ll explore how AppLovin’s move into self-service e-commerce...

Recent quarterly results put Arm Holdings (NasdaqGS:ARM) back in focus, with revenue tied to AI, data center, and premium silicon markets growing, while heavier R&D spending squeezed margins and left sentiment more mixed. See our latest analysis for Arm Holdings. At a share price of $115.75, Arm has had a mixed stretch, with a 30-day share price return of a 7.61% decline and a 1-year total shareholder return of a 4.63% loss. This suggests recent momentum has cooled even as AI related news...

Conference spotlight and recent business momentum Primoris Services (PRIM) is set to present at the 2026 Cantor Global Technology & Industrial Growth Conference in New York on March 10, giving investors fresh context on its recent business momentum. The company has reported very large average backlog growth of 108% over the past two years, alongside 40.4% annual earnings per share growth and a 6 percentage point improvement in free cash flow margin over five years. See our latest analysis for...

Ascendis Pharma A/S recently reported two-year data from its pivotal ApproaCH Trial, showing that once-weekly TransCon CNP (YUVIWEL) maintained consistent improvements in growth and body proportionality in children with achondroplasia, with a generally well-tolerated safety profile and strong trial retention. These longer-term results reinforce YUVIWEL’s clinical profile shortly after its U.S. approval for pediatric achondroplasia and ahead of a key European regulatory decision expected...

Why the leadership reshuffle at Playtika Holding (PLTK) matters for shareholders Playtika Holding (PLTK) is reshaping its senior ranks, with long serving President and CFO Craig Abrahams set to depart on April 1, 2026, and responsibilities shifting to existing insiders. Board chair Robert Antokol will add the President role. Senior finance leader Tae Lee will step in as acting CFO after several years overseeing corporate finance and investor relations. See our latest analysis for Playtika...

Netskope (NTSK) is back in focus after launching its Netskope One AI Security suite, alongside fresh earnings results and new healthcare integrations that together highlight how it is positioning around enterprise AI security. See our latest analysis for Netskope. Despite the launch of Netskope One AI Security and new healthcare integrations, Netskope’s short term share price return has been mixed. The 7 day share price return is 20.75% and the 90 day share price return is 51.40%, which...

Why Customers Bancorp Is On Investors’ Radar Customers Bancorp (CUBI) has drawn attention after a period of weaker share performance. The stock has shown negative returns over the past week, month, and past 3 months, while still delivering a positive 1 year total return. See our latest analysis for Customers Bancorp. Recent trading has been soft, with a 30 day share price return showing an 11.01% decline and a year to date share price return showing a 13.13% decline, even though the 1 year...

EchoStar Corporation has released its full-year 2025 results, reporting revenue of US$15.00 billion, a net loss of US$14.50 billion, and basic and diluted losses per share from continuing operations of US$50.41, all widening significantly from the prior year. Alongside these weak financials, investor attention has shifted toward EchoStar’s move away from declining pay-TV operations toward wireless and MVNO services, and to the potential importance of its non-operating assets such as its...

PBF Energy (PBF) is back in focus after fourth quarter 2025 adjusted earnings per share of $0.66 came in well above expectations, alongside sizeable insider share sales that give investors fresh information to weigh. See our latest analysis for PBF Energy. The strong fourth quarter surprise, heavy insider selling and upcoming Piper Sandler conference appearance have all coincided with powerful momentum. This includes a 30 day share price return of 25.94% and a 1 year total shareholder return...

TG Therapeutics recently reported that a post hoc pooled analysis of the Phase 3 ULTIMATE I and II trials, published in Neurology and Therapy, showed BRIUMVI delivered statistically significant improvements over teriflunomide in relapse rates, MRI activity, and NEDA-3 outcomes for people with highly active relapsing multiple sclerosis over 96 weeks. This peer‑reviewed analysis of a high‑risk subgroup, with benefits emerging by Week 12 and maintained through nearly two years, may strengthen...

The Trump administration previously issued an executive order under the Defense Production Act directing Sable Offshore to restart its long-idled Santa Ynez offshore unit and associated California pipelines, aiming to bolster fuel supplies during the conflict with Iran. This federal push, alongside ongoing court challenges and questions over permitting and safety, has turned Sable Offshore into a high-profile test case for how far Washington can go in overriding state-level environmental...

EverCommerce Inc. recently reported its fourth-quarter and full-year 2025 results, posting Q4 revenue of US$151.15 million and net income of US$6.04 million, while guiding 2026 revenue to a range of US$612.0 million to US$632.0 million. At the same time, the company accelerated its AI focus through initiatives such as the EverHealth Scribe launch and the ZyraTalk acquisition, aiming to deepen workflow integration across its core vertical platforms. We will now examine how EverCommerce’s...

Why AEMO’s directions to Torrens Island matter for AGL Energy (ASX:AGL) The Australian Energy Market Operator’s second direction on AGL Energy’s Torrens Island battery in March 2026, following interventions in November 2025, has constrained operations, reduced revenue opportunities, and highlighted uncertainty around compensation for out of market actions. See our latest analysis for AGL Energy. The recent AEMO directions come at a time when AGL Energy’s A$9.08 share price has a 30 day share...